<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03623295</url>
  </required_header>
  <id_info>
    <org_study_id>NL61564.018.17</org_study_id>
    <nct_id>NCT03623295</nct_id>
  </id_info>
  <brief_title>The Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and B</brief_title>
  <acronym>DYNAMO</acronym>
  <official_title>The Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are large inter-individual differences in the bleeding pattern of patients with
      moderate or mild hemophilia. The major determinant of bleeding phenotype is the level of
      coagulant factor VIII or IX. In hemophilia A, studies addressing the association between
      factor VIII level and the clinical bleeding pattern yield conflicting results. In hemophilia
      B such studies have not yet been performed.

      The primary aim of this project is to analyze the association between factor VIII and factor
      IX levels and the bleeding phenotype. The secondary aim is to analyze potential differences
      in phenotype between hemophilia A and B.

      The project is a multicentre observational cohort study. We will include 500 patients with
      moderate or mild hemophilia A (FVIII 0.02-0.35 IU/mL) and 500 patients with moderate or mild
      hemophilia B (FIX 0.02-0.35 IU/mL) who are 12 to 55 years old. The main cohort study consists
      of clinical data collection, one blood sample and an online questionnaire for patients. Data
      will be collected on the nature and duration of all bleeding episodes, disease and treatment
      characteristics, physical activity level and musculoskeletal status. One blood withdrawal
      will be performed for centralized laboratory assays for FVIII or FIX levels (both one-stage
      and chromogenic assays) and genetic analysis for the most prevalent prothrombotic mutations.
      The online questionnaire for patients focuses on bleeds experienced in the past.

      A subset of 200 patients aged 24 years or older (100 with moderate or mild hemophilia A and
      100 with moderate or mild hemophilia B) will be investigated in more detail by longitudinal
      data collection including analysis of physical joint status, MRI imaging of joints and
      biomarkers for joint damage. This longitudinal observation will consist of two time points
      that lie two years apart, allowing us to identify any changes that occur over the observed
      time period with respect to joint status.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding phenotype</measure>
    <time_frame>Retrospective 10 years</time_frame>
    <description>Annual bleeding rate, annual major bleeding rate, annual spontaneous joint bleeding rate, annual joint bleeding rate</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Hemophilia</condition>
  <arm_group>
    <arm_group_label>Cohort study population</arm_group_label>
    <description>For the main cohort study, we will include 500 patients with moderate or mild hemophilia A and 500 patients with moderate or mild hemophilia B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub study population</arm_group_label>
    <description>A subset of 200 patients of the cohort study population will be investigated in more detail by longitudinal data collection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Blood withdrawal.</description>
    <arm_group_label>Cohort study population</arm_group_label>
    <arm_group_label>Sub study population</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Online questionnaire about the bleeds that patients experienced in the past.</description>
    <arm_group_label>Cohort study population</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI-imaging</intervention_name>
    <description>MRI imaging of joints.</description>
    <arm_group_label>Sub study population</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical examination</intervention_name>
    <description>Physical examination of joint status.</description>
    <arm_group_label>Sub study population</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biospecimens to be retained for future research:

        -  Blood

        -  Urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited from Hemophilia Treatment Centers participating in the INSIGHT
        consortium, a well-established and productive group of investigators from European
        countries, Canada and Australia.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate or mild hemophilia A (FVIII:C 0.02-0.35 IU/mL) or hemophilia B (FIX:C
             0.02-0.35 IU/mL)

          -  Age from 12 up to and including 55 years

        Exclusion Criteria:

          -  Other clotting disorder

          -  Participation in another trial with an investigational product

          -  Comorbidity affecting the musculoskeletal status

          -  Clinically relevant inhibitor status at present or in the past

          -  Hemophilia B Leyden

          -  Use of anticoagulants
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karin Fijnvandraat</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne-Fleur Zwagemaker</last_name>
    <phone>+31205668668</phone>
    <email>a.zwagemaker@amc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabienne Kloosterman</last_name>
    <phone>+31205668668</phone>
    <email>f.r.kloosterman@amc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>INSIGHT study team</last_name>
      <phone>+31205668668</phone>
      <email>insight@amc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>INSIGHT study team</last_name>
      <phone>+31205668668</phone>
      <email>insight@amc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multicentre: Leuven, Brussels</name>
      <address>
        <city>Multiple Locations</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>INSIGHT study team</last_name>
      <phone>+31205668668</phone>
      <email>insight@amc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multicentre: Vancouver, Toronto, Hamilton</name>
      <address>
        <city>Multiple Locations</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>INSIGHT study team</last_name>
      <phone>+31205668668</phone>
      <email>insight@amc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>INSIGHT study team</last_name>
      <phone>+31205668668</phone>
      <email>insight@amc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multicentre: Bonn, Berlin, Frankfurt, München, Hamburg</name>
      <address>
        <city>Multiple Locations</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>INSIGHT study team</last_name>
      <phone>+31205668668</phone>
      <email>insight@amc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multicentre: Florence, Rome, Parma, Milan, Turin</name>
      <address>
        <city>Multiple Locations</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>INSIGHT study team</last_name>
      <phone>+31205668668</phone>
      <email>insight@amc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>INSIGHT study team</last_name>
      <phone>+31205668668</phone>
      <email>insight@amc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>INSIGHT study team</last_name>
      <phone>+31205668668</phone>
      <email>insight@amc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>INSIGHT study team</last_name>
      <phone>+31205668668</phone>
      <email>insight@amc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>INSIGHT study team</last_name>
      <phone>+31205668668</phone>
      <email>insight@amc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>INSIGHT study team</last_name>
      <phone>+31205668668</phone>
      <email>insight@amc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>INSIGHT study team</last_name>
      <phone>+31205668668</phone>
      <email>insight@amc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Utrecht University Medical Center</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>INSIGHT study team</last_name>
      <phone>+31205668668</phone>
      <email>insight@amc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Máxima Medical Center</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>INSIGHT study team</last_name>
      <phone>+31205668668</phone>
      <email>insight@amc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multicentre: Valencia, Madrid, Barcelona</name>
      <address>
        <city>Multiple Locations</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>INSIGHT study team</last_name>
      <phone>+31205668668</phone>
      <email>insight@amc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multicentre: Manchester, London, Liverpool, Glasgow, Cardiff, Sheffield</name>
      <address>
        <city>Multiple Locations</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>INSIGHT study team</last_name>
      <phone>+31205668668</phone>
      <email>insight@amc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>August 6, 2018</last_update_submitted>
  <last_update_submitted_qc>August 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Karin Fijnvandraat</investigator_full_name>
    <investigator_title>Professor of Pediatric Hematology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

